Dr. Ramalingam on the Role of Osimertinib in EGFR T790M-Positive Advanced NSCLC
December 7th 2016
Suresh S. Ramalingam, MD, professor, Department of Hematology and Medical Oncology, Deputy Director, Winship Cancer Institute of Emory University, discusses the role of osimertinib in the treatment of patients with EGFR T790M-positive advanced non-small cell lung cancer, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.